Zhongzhi Pharmaceutical Holdings Limited (3737.HK)
- Previous Close
0.930 - Open
0.910 - Bid 0.900 x --
- Ask 0.920 x --
- Day's Range
0.900 - 0.920 - 52 Week Range
0.820 - 1.280 - Volume
354,000 - Avg. Volume
291,929 - Market Cap (intraday)
759.37M - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
7.50 - EPS (TTM)
0.120 - Earnings Date Mar 26, 2025
- Forward Dividend & Yield 0.08 (8.60%)
- Ex-Dividend Date May 23, 2025
- 1y Target Est
--
Zhongzhi Pharmaceutical Holdings Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company operates through Pharmaceutical Manufacturing and Operation of Chain Pharmacies segments. It also provides Chinese patent medicines and decoction pieces under the Zeus, Liumian, and Caojinghua brand names. In addition, the company manufactures and sells food and Chinese herbs; offers detection and testing services; and manages properties. Further, the company engages in the wholesale of pharmaceutical products; and provision of traditional Chinese medicine service. Zhongzhi Pharmaceutical Holdings Limited was founded in 1993 and is headquartered in Zhongshan, the People's Republic of China. Zhongzhi Pharmaceutical Holdings Limited is a subsidiary of Crystal Talent Investment Group Limited.
www.zeus.cn2,577
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 3737.HK
View MorePerformance Overview: 3737.HK
Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 3737.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 3737.HK
View MoreValuation Measures
Market Cap
784.68M
Enterprise Value
930.00M
Trailing P/E
7.80
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.33
Price/Book (mrq)
0.65
Enterprise Value/Revenue
0.39
Enterprise Value/EBITDA
3.23
Financial Highlights
Profitability and Income Statement
Profit Margin
4.30%
Return on Assets (ttm)
4.14%
Return on Equity (ttm)
8.84%
Revenue (ttm)
2.21B
Net Income Avi to Common (ttm)
95.21M
Diluted EPS (ttm)
0.120
Balance Sheet and Cash Flow
Total Cash (mrq)
199.69M
Total Debt/Equity (mrq)
16.82%
Levered Free Cash Flow (ttm)
27.57M